Gene Therapy for severe Hemophilia has new Phase I : labiotech

according to labiotech

Gene Therapy for severe Hemophilia has new Phase I

Gene Therapy for severe Hemophilia has new Phase I

uniQure has new data from the Phase I/II trial of its gene therapy for Hemophilia B, a rare genetic disorder.After 9 months, the therapy maintains 75% reduction of transfusions.A good sign for the therapy's durability.


in like manner thestreet

Biomarin Hemophilia Gene Therapy Advances on Strong Study Results

Biomarin Hemophilia Gene Therapy Advances on Strong Study Results

Roche Beats First-Half Forecasts as Cancer Drug Sales RiseThe Swiss pharmaceuticals company confirms a forecast for full-year sales to increase in the low to mid-single digits, and for earnings per share to grow faster than revenue.


besides dddmag

BioMarin Announces Positive Trial Data for Hemophilia A Gene Therapy

BioMarin Announces Positive Trial Data for Hemophilia A Gene Therapy

BioMarin announced positive interim results of an open-label Phase 1/2 study of BMN 270, an investigational gene therapy treatment for severe hemophilia A at the XXXII International Congress of the World Federation of Hemophilia (WFH).The data was presented in the Late Breaking Gene Therapy session by John Pasi, Professor of Haemostasis and Thrombosis, Barts and the London School of Medicine, Honorary Consultant Haematologist, The Royal London Hospital, and a lead investigator of the study.The data presented at the congress is an update since the Company reported initial results on this same study on April 20, 2016.


in like manner forbes

BioMarin Gene Therapy Yields Dramatic Results In Hemophilia

BioMarin Gene Therapy Yields Dramatic Results In Hemophilia